Search our Database of Scientific Publications and Authors

I’m looking for a

    4349 results match your criteria Macular Edema Diabetic

    1 OF 87

    Ethnic Differences in the Prevalence and Risk Factors of Diabetic Retinopathy: The Singapore Epidemiology of Eye Diseases Study.
    Ophthalmology 2017 Dec 4. Epub 2017 Dec 4.
    Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore; Duke-National University of Singapore Medical School, Singapore. Electronic address:
    Purpose: To evaluate the prevalence and risk factors for diabetic retinopathy (DR) in the Singapore Epidemiology of Eye Diseases (SEED) Study.

    Design: Population-based, cross-sectional study.

    Participants: Persons of Malay, Indian, and Chinese ethnicity aged 40+ years, living in Singapore. Read More

    Management of diabetic macular edema in Japan: a review and expert opinion.
    Jpn J Ophthalmol 2017 Dec 5. Epub 2017 Dec 5.
    Kyushu University Hospital, Fukuoka, Japan.
    Diabetic retinopathy is a frequent cause of visual impairment in working-age adults (≥ 30 years) and in Japan is most commonly observed in those aged 50-69 years. Diabetic macular edema (DME) is one of the main causes of vision disturbance in diabetic retinopathy, which is a clinically significant microvascular complication of diabetes. Anti-vascular endothelial growth factor (VEGF) therapy is becoming the mainstay of treatment for DME. Read More

    Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occulsions.
    Asia Pac J Ophthalmol (Phila) 2017 Nov-Dec;6(6):546-553
    University of Illinois at Chicago, Chicago, IL, United States.
    The use of anti-vascular endothelial growth factor (VEGF) therapy in ophthalmology has profoundly changed our management and treatment of conditions such as cystoid macular edema, diabetic macular edema, choroidal neovascularization, and other proliferative retinopathies. Although initially used for the treatment of choroidal neovascularization in neovascular age-related macular degeneration, their application has spread rapidly for other indications as their outcomes have often outperformed previously existing treatments. Retinal vein occlusion (RVO) continues to be one of the leading causes of vision loss secondary to macular edema, in addition to macular ischemia and neovascularization in more severe cases. Read More

    Diet and risk of diabetic retinopathy: a systematic review.
    Eur J Epidemiol 2017 Dec 4. Epub 2017 Dec 4.
    Inserm U1018, Institut Gustave Roussy, CESP, 114 Rue Edouard Vaillant, 94805, Villejuif Cedex, France.
    Diabetic retinopathy is a microvascular complication of diabetes that threatens all individuals with diabetes, leading to vision loss or blindness if left untreated. It is frequently associated with diabetic macular edema, which can occur at any point during the development of diabetic retinopathy. The key factors known to lead to its development include hyperglycemia, hypertension, and the duration of diabetes. Read More

    The Role of Focal Laser in the Anti-Vascular Endothelial Growth Factor Era.
    Ophthalmol Eye Dis 2017 21;9:1179172117738240. Epub 2017 Nov 21.
    Retina Consultants of Alabama, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
    Introduction: To review important studies examining focal laser for diabetic macular edema (DME), to examine real-world data regarding actual treatments patients are receiving, to present long-term visual outcomes in real-world practice, and to suggest an evidence-based approach for the use of focal laser.

    Methods: This study is a review of landmark studies evaluating focal laser and pharmacologic therapy for DME. In addition, the authors include a retrospective review of 102 consecutive eyes of 53 patients in our practice setting in rural Alabama. Read More

    Six-month postoperative outcomes of intraoperative OCT-guided surgical cystotomy for refractory cystoid macular edema in diabetic eyes.
    Clin Ophthalmol 2017 23;11:2099-2105. Epub 2017 Nov 23.
    Eye Center, Shinseikai Toyama Hospital, Imizu, Toyama, Japan.
    Purpose: This study evaluated the outcomes of surgical cystotomy for recurrent diabetic cystoid macular edema (CME).

    Patients And Methods: We analyzed 20 eyes with a clinical diagnosis of diabetic retinopathy and refractory CME. Release of vitreoretinal adhesion, epiretinal membrane (ERM) and internal limiting membrane (ILM) peeling and cystotomy guided by intraoperative optical coherence tomography (iOCT) were performed in every patient. Read More

    Structure-guided Discovery of Novel, Potent and Orally Bioavailable Inhibitors of Lipoprotein-associated Phospholipase A2.
    J Med Chem 2017 Dec 1. Epub 2017 Dec 1.
    Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a promising therapeutic target for atherosclerosis, Alzheimer's disease and diabetic macular edema. Here we report the identification of novel sulfonamide scaffold Lp-PLA2 inhibitors derived from a relatively weak fragment. Similarity searching on this fragment followed by molecular docking leads to the discovery of a micromolar inhibitor with 300-fold potency improvement. Read More

    [Recommendations for the use of ranibizumab in diabetic macular edema at IMSS].
    Rev Med Inst Mex Seguro Soc 2017 Nov-Dec;55(6):758-767
    aJefatura del Servicio de Oftalmología, Hospital General "Dr. Gaudencio González Garza", Centro Médico Nacional La Raza, Ciudad de México.
    Diabetic macular edema can occur at any stage of diabetic retinopathy. It represents the main cause of vision loss in diabetes type I and II with a prevalence of 3-10% in diabetic patients of the Instituto Mexicano del Seguro Social (IMSS). Our aim is to elaborate treatment guidelines and provide recommendations for the use of intravitreal ranibizumab for diabetic medical edema at IMSS. Read More

    Retina 2017 Nov 22. Epub 2017 Nov 22.
    *Hospital of Neurology, Ophthalmology, Lyon, France;†Ophthalmology, Croix-Rousse University Hospital, Lyon, France;‡Ophthalmology, Desgenettes Military Hospital, Lyon, France; and§Ezus Lyon, Biostatistique, Lyon, France.
    Purpose: To evaluate the association between obstructive sleep apnea and diabetic macular edema (DME) in patients with Type II diabetes, using the apnea-hypopnea index and other nocturnal hypoxemia parameters.

    Methods: This cross-sectional, case-control study included 99 patients with Type II diabetes: the first group included patients with DME (DME+ group) and the second patients without DME (DME- group). Polysomnography was performed in all patients. Read More

    Retina 2017 Nov 22. Epub 2017 Nov 22.
    Department of Ophthalmology, *University of Oxford, Oxford, Oxfordshire, United Kingdom;†Department of Ophthalmology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom;‡Department of Ophthalmology, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom; and Department of Ophthalmology,§University Hospital Birmingham, Birmingham, United Kingdom.
    Purpose: To compare retinal sensitivity and central retinal thickness in patients with focal diabetic macular edema (DME) and edema secondary to branch retinal vein occlusion (BRVO).

    Methods: In this consecutive, cross-sectional, observational study, patients with either DME or BRVO underwent measurements for best-corrected visual acuity, microperimetry, and spectral domain optical coherence tomography. Retinal thickness and sensitivity were measured using Optos Spectral optical coherence tomography/scanning laser ophthalmoscopy (Optos plc, Dunfermline, Scotland, United Kingdom). Read More

    The Role of Glycemic Control and Variability in Diabetic Retinopathy.
    Diabetes Ther 2017 Nov 30. Epub 2017 Nov 30.
    2nd Department of Ophthalmology, University of Athens, Athens, Greece.
    Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus (DM) and is considered the leading cause of visual impairment in working-aged adults worldwide. The duration of DM and hyperglycemia have been associated with DR, although the exact role in the pathogenesis of DR and diabetic macular edema remains controversial. As a result, a reasonable question arising is whether control of blood glucose levels may alter the course of DR. Read More

    Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment.
    Invest Ophthalmol Vis Sci 2017 Nov;58(13):5958-5967
    Department of Ophthalmology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
    Purpose: To investigate the association between hyperreflective dots (HRDs) on spectral-domain optical coherence tomography (SD-OCT) and response to intravitreal bevacizumab (IVB) or dexamethasone injection in eyes with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).

    Methods: A retrospective review was conducted involving patients with DME or macular edema due to RVO. Patients with treatment-naïve macular edema were initially treated with three consecutive IVB injections and classified based on the treatment response to bevacizumab. Read More

    Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study.
    Clin Ophthalmol 2017 14;11:1995-2002. Epub 2017 Nov 14.
    Department of Ophthalmology, Military Medical Academy, St Petersburg, Russia.
    Purpose: To study vitreoretinal interface (VRI) abnormalities in diabetic macular edema (DME) and the influence of these on the effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) therapy.

    Methods: VRI status and central retinal thickness (CRT) were evaluated using line and 3D-reference scans obtained using spectral domain-optical coherence tomography RTVue-100 before and 1 month after intravitreal anti-VEGF injection (IVI). VRI status was categorized into five subgroups: normal VRI, retinal surface wrinkling associated with the eccentric epiretinal membrane (ERM), ERM involving the macular center, vitreomacular adhesion (VMA), and vitreomacular traction (VMT). Read More

    [Vitreomacular Traction Following Anti-VEGF Therapy - Two Cases].
    Klin Monbl Augenheilkd 2017 Nov 27. Epub 2017 Nov 27.
    Augenklinik Herzog Carl Theodor, München.
    Vitreomacular traction syndrome (VMTS) is defined as an incomplete or anomalous posterior vitreous detachment resulting in tractional forces at the macular region. In the context of anti-VEGF therapy, the formation of vitreoretinal traction has mainly been reported as a potential complication of VEGF inhibition in ischemic proliferative retinal disease, such as proliferative diabetic retinopathy. In this report, we present two patients who developed VMTS during anti-VEGF therapy for exudative age-related macular degeneration and diabetic macular edema. Read More

    Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy.
    Curr Eye Res 2017 Nov 27:1-8. Epub 2017 Nov 27.
    a Department of Ophthalmology , Medical University Innsbruck , Innsbruck , Austria.
    Purpose: To analyze the interaction between aflibercept and galectin-1 and evaluate the plasma levels of galectin-1 and vascular endothelial growth factor (VEGF)-A after intravitreal injection of aflibercept in patients with diabetic retinopathy (DR).

    Methods: Interaction of galectin-1 with aflibercept was determined via immunoprecipitation. Seventeen patients with type 2 diabetes and diabetic macular edema (DME) were each treated with a single intravitreal injection of aflibercept (2. Read More

    Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy.
    Sci Rep 2017 Nov 23;7(1):16168. Epub 2017 Nov 23.
    Laboratory of Ocular Cell Biology and Visual Science, Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, 060-8638, Japan.
    Diabetic retinopathy (DR) is an inflammatory and progressive vaso-occlusive disease resulting in angiogenesis. Galectin-1 is a hypoxia-induced angiogenic factor associated with cancer and proliferative DR. Here we reveal a significant upregulation of galectin-1 in eyes of DR patients along with progression of clinical stages beginning from the pre-ischemic, inflammatory stage with diabetic macular edema, but not in eyes with non-diabetic retinal vascular occlusions. Read More

    Association of Abnormal Renal Profiles and Proliferative Diabetic Retinopathy and Diabetic Macular Edema in an Asian Population With Type 2 Diabetes.
    JAMA Ophthalmol 2017 Nov 22. Epub 2017 Nov 22.
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
    Importance: The comorbidity of chronic kidney disease and diabetic retinopathy (DR) is well known. However, to our knowledge, no cohort study has demonstrated the effect of chronic kidney disease on the development or progression of DR.

    Objective: To investigate the association of chronic kidney disease with the development of DR and diabetic macular edema (DME) in type 2 diabetes. Read More

    Photobiodulation Inhibits Long-Term Structural and Functional Lesions of Diabetic Retinopathy.
    Diabetes 2017 Nov 22. Epub 2017 Nov 22.
    Department of Medicine, Case Western Reserve University, Cleveland, OH; Department of Ophthalmology,
    Previous studies demonstrated that brief (3-4 minutes), daily application of light at 670nm to diabetic rodents inhibited molecular and pathophysiologic processes implicated in the pathogenesis of diabetic retinopathy (DR), and reversed diabetic macular edema in small numbers of patients studied. Whether or not this therapy would inhibit the neural and vascular lesions that characterize the early stages of the retinopathy was unknown. We administered photobiomodulation (PBM) therapy daily for 8 months to streptozotocin-diabetic mice, and assessed effects of PBM on visual function, retinal capillary permeability, and capillary degeneration using published methods. Read More

    The EPAC-Rap1 pathway prevents and reverses cytokine-induced retinal vascular permeability.
    J Biol Chem 2017 Nov 20. Epub 2017 Nov 20.
    University of Michigan, United States
    Increased retinal vascular permeability contributes to macular edema, a leading cause of vision loss in eye pathologies such as diabetic retinopathy, age-related macular degeneration, and central retinal vein occlusions. Pathological changes in vascular permeability are driven by growth factors such as VEGF and by pro-inflammatory cytokines such as TNF-α. Identifying the pro-barrier mechanisms that block vascular permeability and restore the blood-retinal barrier (BRB) may lead to new therapies. Read More

    A benchmark study of automated intra-retinal cyst segmentation algorithms using optical coherence tomography B-scans.
    Comput Methods Programs Biomed 2018 Jan 12;153:105-114. Epub 2017 Oct 12.
    Department of Computer Science and Engineering, National Institute of Technology Karnataka, Surathkal, India.
    (background And Objectives): Retinal cysts are formed by accumulation of fluid in the retina caused by leakages from inflammation or vitreous fractures. Analysis of the retinal cystic spaces holds significance in detection and treatment of several ocular diseases like age-related macular degeneration, diabetic macular edema etc. Thus, segmentation of intra-retinal cysts and quantification of cystic spaces are vital for retinal pathology and severity detection. Read More

    Retin Cases Brief Rep 2017 Nov 16. Epub 2017 Nov 16.
    *Department of Research, Wagner Macula and Retina Center, Virginia Beach, Virginia; and†Department of Research, Eastern Virginia Medical School, Virginia Beach, Virginia.
    Purpose: The objective of this study was to evaluate patient safety and tolerance of consecutive bilateral intravitreal dexamethasone (Ozurdex) injections during a single visit for the treatment of cystoid macular edema secondary to retinal vein occlusion, diabetic macular edema, or noninfectious posterior uveitis.

    Methods: This was a retrospective single-center institutional review board-approved study from March 1, 2013, through August 1, 2016. All patients had a complete ophthalmologic examination and optical coherence tomography imaging. Read More

    Association Between Perceived Barriers to Diabetes Self-management and Diabetic Retinopathy in Asian Patients With Type 2 Diabetes.
    JAMA Ophthalmol 2017 Nov 16. Epub 2017 Nov 16.
    Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
    Importance: A patient's perceived barriers to diabetes self-management (DSM) may affect his or her risk of diabetic retinopathy (DR); however, few studies have examined this association.

    Objective: To examine the association between perceived barriers to DSM and the severity spectrum of DR in Asian patients with type 2 diabetes.

    Design, Setting, And Participants: A cross-sectional clinic-based study, the Singapore Diabetes Management Project, was conducted from December 28, 2010, to March 20, 2013, at the Singapore National Eye Centre, a tertiary eye care institute. Read More

    Cataract Surgery in Patients with Diabetes: Management Strategies.
    Semin Ophthalmol 2017 Nov 16:1-8. Epub 2017 Nov 16.
    a Joslin Diabetes Center , Beetham Eye Institute , Boston , MA , USA.
    Diabetes is a chronic systemic disease that affects nearly one in eight adults worldwide. Ocular complications, such as cataract, can lead to significant visual impairment. Among the worldwide population, cataract is the leading cause of blindness, and patients with diabetes have an increased incidence of cataracts which mature earlier compared to the rest of the population. Read More

    Outcomes of intravitreal bevacizumab and macular photocoagulation for treatment of diabetic macular edema in a tertiary care eye hospital, Karachi.
    Pak J Med Sci 2017 Sep-Oct;33(5):1215-1219
    Saleh Memon, Isra Ophthalmic Research & Development Center, Al-Ibrahim Eye Hospital, Karachi, Pakistan.
    Objective: To study the outcomes of intravitreal injection of Bevacizumab and laser photocoagulation in the treatment of diabetic macular edema (DME).

    Methods: Seventy-two eyes of 59 patients with diabetic macular edema were divided into two groups of 41 eyes (Group-A) and 31 eyes (Group-B). Subjects in group-A were treated with three intravitreal injections of Bevacizumab (IVB), and that of group-B with macular photocoagulation. Read More

    Optical coherence tomography angiography in patients with diabetic retinopathy treated with anti-VEGF intravitreal injections: Case report.
    Medicine (Baltimore) 2017 Nov;96(45):e8379
    aDepartment of Ophthalmology, School of Medicine in Katowice bProfessor K. Gibinski University Clinical Center, Medical University of Silesia, Katowice, Poland.
    Purpose: To present optical coherence tomography angiography (OCTA) features in patients with diabetic retinopathy (DR) at the baseline and in response to treatment with anti-VEGF intravitreal injections. To investigate the role of OCTA in management of patients with DR.

    Methods: Retrospective case series showing primary outcomes of 3 patients with DR and diabetic macular edema. Read More

    Retina 2017 Nov 10. Epub 2017 Nov 10.
    *Feinberg School of Medicine, Northwestern University, Chicago, Illinois; †Jaeb Center for Health Research, Tampa, Florida; ‡Paducah Retinal Center, Paducah, Kentucky; §Washington University School of Medicine, St. Louis, Missouri; ¶Medical College of Wisconsin, Milwaukee, Wisconsin; **Department of Ophthalmology, Duke University, Durham, North Carolina; and ††Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
    Purpose: Compare changes in retinal nerve fiber layer (RNFL) thickness between eyes assigned to intravitreous ranibizumab or panretinal photocoagulation and assess correlations between changes in RNFL and visual field sensitivity and central subfield thickness.

    Methods: Eyes with proliferative diabetic retinopathy were randomly assigned to ranibizumab or panretinal photocoagulation. Baseline and annual follow-up spectral domain optical coherence tomography RNFL imaging, optical coherence tomography macular imaging, and automated static perimetry (Humphrey visual field 60-4 algorithm) were performed. Read More

    Relationship between visual outcomes and retinal fluid resorption in patients with diabetic macular edema treated with ranibizumab.
    J Fr Ophtalmol 2017 Dec 11;40(10):839-843. Epub 2017 Nov 11.
    Ophthalmology department, Avicenne hospital, DHU vision and handicaps, 125, rue de Stalingrad, 93000 Bobigny, France; Inserm, U_968, CNRS, UMR_7210, institut de la vision, Sorbonne Universities, UPMC Université Paris 06, 75012 Paris, France. Electronic address:
    Purpose: We assessed the relationship between visual acuity (VA) recovery and a qualitative criterion - complete retinal fluid resorption (CRFR) - among patients treated with ranibizumab for diabetic macular edema (DME) METHODS: All consecutive diabetic patients with central DME received a loading dose of 3 monthly injections of ranibizumab 0.5mg, followed by retreatments on an as-needed basis as determined by monthly follow-up. Patients were divided into 3 groups: CRFR (defined as a CRT <300μm and restoration of the foveolar pit) with BCVA≤70 letters (group 1: G1), CRFR with BCVA>70 letters (20/40) (G2), and persistent retinal fluid throughout the follow-up (G3). Read More

    Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    JAMA Ophthalmol 2017 Nov 11. Epub 2017 Nov 11.
    Joslin Diabetes Center, Beetham Eye Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
    Importance: Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes than continued anti-VEGF therapy alone.

    Objective: To compare continued intravitreous ranibizumab alone with ranibizumab plus intravitreous dexamethasone implant in eyes with persistent DME. Read More

    Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study.
    Ophthalmol Ther 2017 Nov 10. Epub 2017 Nov 10.
    Department of Ophthalmology, Leicester Royal Infirmary, Infirmary Square, Leicester, UK.
    Introduction: It is hypothesized that using fluocinolone acetonide (FAc) implants such as Iluvien for the treatment of diabetic macular edema (DME) may reduce the total number of intravitreal injections and clinic visits, resulting in an overall treatment cost reduction. The primary aim of this study is to identify the real-world cost savings achievable in a tertiary National Health Service (NHS) hospital.

    Methods: A retrospective cost analysis study was conducted. Read More

    Mechanisms of macular edema: Beyond the surface.
    Prog Retin Eye Res 2017 Nov 7. Epub 2017 Nov 7.
    INSERM, UMRS1138, Team 17, From Physiopathology of Ocular Diseases to Clinical Development, Université Paris Descartes Sorbonne Paris Cité, Centre de Recherche des Cordeliers, 15 rue de l'Ecole de Médecine, 75006 Paris, France; Ophtalmopole, Cochin Hospital, AP-HP, Assistance Publique Hôpitaux de Paris, 24 rue du Faubourg Saint-Jacques, 75014 Paris, France; Faculty of Biology and Medicine, University of Lausanne, Rue du Bugnon 21, 1011 Lausanne, Switzerland. Electronic address:
    Macular edema consists of intra- or subretinal fluid accumulation in the macular region. It occurs during the course of numerous retinal disorders and can cause severe impairment of central vision. Major causes of macular edema include diabetes, branch and central retinal vein occlusion, choroidal neovascularization, posterior uveitis, postoperative inflammation and central serous chorioretinopathy. Read More

    Retinal Vascular Caliber Changes After Topical Nepafenac Treatment for Diabetic Macular Edema.
    Curr Eye Res 2017 Nov 9:1-5. Epub 2017 Nov 9.
    a Department of Ophthalmology , Okmeydanı Training and Research Hospital , Istanbul , Turkey.
    Purpose: To assess changes in retinal vascular caliber in response to short-term use of nepafenac eye drops in patients with mild diabetic macular edema.

    Materials And Methods: Thirty-four patients with previously untreated bilateral mild diabetic macular edema were included in this prospective study. For each participant, one eye was randomly assigned to nepafenac treatment (0. Read More

    Acta Clin Croat 2017 03;56(1):124-32
    Diabetes is one of the leading public health problems worldwide. Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of diabetes is the primary goal of treatment and the basic way of preventing and stopping the progression of DME. Read More

    Acta Clin Croat 2017 03;56(1):124-32
    Diabetes is one of the leading public health problems worldwide. Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of diabetes is the primary goal of treatment and the basic way of preventing and stopping the progression of DME. Read More

    Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study.
    Graefes Arch Clin Exp Ophthalmol 2017 Nov 8. Epub 2017 Nov 8.
    Allergan plc, Irvine, CA, USA.
    Purpose: The purpose of this study was to evaluate the safety and efficacy of dexamethasone intravitreal implant 0.7 mg (DEX) for treatment of macular edema associated with retinal vein occlusion (RVO).

    Methods: This study was a six-month, randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial with a 2-month open-label study extension. Read More

    Bullous Exudative Retinal Detachment after Retinal Pattern Scan Laser Photocoagulation in Diabetic Retinopathy.
    Case Rep Ophthalmol 2017 Sep-Dec;8(3):475-481. Epub 2017 Oct 3.
    Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.
    Laser retinal photocoagulation is the gold standard treatment for diabetic retinopathy. We describe 3 cases in which bullous exudative retinal detachment (ERD) developed after pattern scan laser photocoagulation (PASCAL) in diabetic retinopathy. ERD spontaneously resolved in all 3 cases with various visual courses. Read More

    Recurrent Diabetic Macular Edema: What to Do.
    Case Rep Ophthalmol 2017 Sep-Dec;8(3):465-474. Epub 2017 Sep 27.
    Department of Ophthalmology, Hospital Pedro Hispano, Matosinhos, Portugal.
    Diabetic macular edema (DME) is a leading cause of blindness in the working population. Herein, we report the case of a patient with recurrent DME for about 6 years, uncontrolled by several medical and surgical treatments, that was successfully treated with a single sustained-release fluocinolone acetonide intravitreal implant in her right eye. The affected eye had presented a visual acuity of 2/10 and a central macular thickness of 488 µm prior to the injection. Read More

    Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population.
    Oman J Ophthalmol 2017 Sep-Dec;10(3):177-183
    Department of Family Medicine and Public Health, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.
    Purpose: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME).

    Materials And Methods: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thickness. All eyes were injected with a single IVT injection of preservative free triamcinolone acetonide (TA) with dose of 4 mg. Read More

    Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Real-Life Data from a Prospective Study and Predictive Factors for Visual Outcome.
    Diabetes Ther 2017 Dec 6;8(6):1393-1404. Epub 2017 Nov 6.
    Retina Department, Red Cross "Korgialeneio-Benakeio" Hospital, Athens, Greece.
    Introduction: The purpose of the study was to evaluate the long-term anatomical and functional outcomes in patients with diabetic macular edema (DME) treated with intravitreal dexamethasone implant and to determine the predictive factors for the final visual outcome.

    Methods: The study included 54 patients with DME refractory to previous antivascular endothelial growth factor (anti-VEGF) who were treated with intravitreal dexamethasone implant. Predictive factors for visual outcome were assessed. Read More

    Outcomes of Intravitreal Dexamethasone Implant in the Treatment of Recalcitrant Diabetic Macular Edema.
    Turk J Ophthalmol 2017 Oct 27;47(5):274-278. Epub 2017 Oct 27.
    Gülhane Training and Research Hospital, Ophthalmology Clinic, Ankara, Turkey.
    Objectives: To investigate the efficacy and safety of intravitreal dexamethasone (OZURDEX®) implantation in patients with recalcitrant diabetic macular edema.

    Materials And Methods: This is a retrospective non-randomized study of patients who underwent intravitreal dexamethasone implantation for recalcitrant diabetic macular edema. Main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and incidence of ocular side effects. Read More

    Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection.
    J Vitreoretin Dis 2017 May 1;1(3):169-174. Epub 2017 Feb 1.
    Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Beaumont Eye Institute, Royal Oak, MI.
    Purpose: With multiple anti-vascular endothelial growth factor and steroid therapies available for diabetic macular edema (DME), there is a need for early determination of the best treatment for a particular patient to prevent irreversible vision loss from chronic DME. In this study, we classify patients as responders or non-responders to anti-vascular endothelial growth factor (VEGF) monotherapy in the treatment of DME after a single anti-VEGF injection.

    Methods: The study was designed as a single center, retrospective, interventional case series. Read More

    A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®).
    Case Rep Ophthalmol Med 2017 2;2017:6369085. Epub 2017 Oct 2.
    Dr. Resat Belger Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
    Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion. By reporting this case we aimed to report a new side effect of 0. Read More

    Retina 2017 Oct 30. Epub 2017 Oct 30.
    Department of Ophthalmology, University of Bonn, Bonn, Germany.
    Purpose: To determine the minimal optical coherence tomography B-scan density for reliable detection of intraretinal and subretinal fluid.

    Methods: Spectral domain optical coherence tomography raster scanning (Spectralis; Heidelberg Engineering, Heidelberg, Germany) using a scan field of 20° × 20° of 97 B-scans with an interscan distance (ISD) of 60 μm was performed in 150 eyes of 150 consecutive patients at monitoring visits for intravitreal anti-vascular endothelial growth factor therapy. Using custom software, every other B-scan was repeatedly deleted to generate additional data sets with an ISD of 120 μm (49 B-scans), 240 μm (25 B-scans), and 480 μm (13 B-scans). Read More

    Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: A Bayesian network meta-analysis.
    Biomed Pharmacother 2017 Oct 26;97:293-299. Epub 2017 Oct 26.
    Tongji Eye Institute, School of Medicine, Tongji University, 1239 Siping Road, Yangpu District, Shanghai 200092, China. Electronic address:
    Aims: To assess the effects of laser photocoagulation as monotherapy or adjuvant therapy for the treatment of DME.

    Methods: A search of the Cochrane Library, Pubmed, Embase, and the registry for randomized clinical trials comparing any two treatments of interest (SDMLP monotherapy, CLP monotherapy, CLP plus anti-VEGF therapy) was performed. Read More

    Novel strategy for Screening of Diabetic Retinopathy.
    J Diabetes Investig 2017 Nov 1. Epub 2017 Nov 1.
    Department of Ophthalmology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-Ku, Kawasaki, 216-8511, Japan.
    Diabetic retinopathy is the most common cause of blindness in adults. Visual deficiency is mainly caused from clinically significant macular edema or vision-threatening proliferative diabetic retinopathy. Recent advances in the treatment modalities such as laser photocoagulation or with intraocular glucocorticoids or anti-vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision. Read More

    ILM peeling in nontractional diabetic macular edema: review and metanalysis.
    Int Ophthalmol 2017 Oct 31. Epub 2017 Oct 31.
    Department of Medicine and Health Sciences, University of Molise, Via Francesco De Sanctis 1, 86100, Campobasso, Italy.
    Purpose: To evaluate the effect of internal limiting membrane (ILM) peeling during vitrectomy for nontractional diabetic macular edema.

    Methods: PUBMED, MEDLINE and CENTRAL were reviewed using the following terms (or combination of terms): diabetic macular edema, nontractional diabetic macular edema, internal limiting membrane peeling, vitrectomy, Müller cells. Randomized and nonrandomized studies were included. Read More

    Current Anti-Integrin Therapy for Ocular Disease.
    Semin Ophthalmol 2017 Oct 31:1-9. Epub 2017 Oct 31.
    a Research Department , Asociación para Evitar la Ceguera en México I.A.P , Mexico City , Mexico.
    The integrin family of cell adhesion molecules mediates homeostasis, signal transduction, and various other interactions between the cell and the extracellular matrix. Integrins are type-1 transmembrane glycoproteins located on the cell surface, widely expressed in leukocytes, which play an important role in the inflammatory pathway. The purpose of this review is to summarize the current state of anti-integrin therapy and to assess ongoing clinical trials in ocular disease. Read More

    1 OF 87